Rohan didn't say he was talking to big pharma about this but did say he anticipated interest from both larger biotechs and pharma.
Big pharma will be interested in this. As I previously mentioned, Pfizer was asking for submissions on PKD from academic institutions last year and if PKD is interesting/big enough for Pfizer to want to develop a therapeutic, I think it's fair to say that it would be the same for many other big pharma.
What I've captured below comes from a flyer put out by Uniquest here at UQ in Queensland (my highlighting).
Ann: Polycystic Kidney Disease Program Presentation, page-6
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $606.5M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 12.5¢ | $17.86K | 137.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1081168 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 505604 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |